Key Points
- Matthew Winton, a CervoMed insider, bought 10,000 shares on Nov. 14 at $7.57 each for a total of $75,700, and now directly owns those shares (SEC filing disclosed).
- The company reported quarterly EPS of ($0.84), missing estimates and posting revenue of $0.32M versus $1.43M expected; CervoMed has a market cap near $75.97M and a 1‑year share range of $1.80–$16.94.
- Analyst sentiment is mixed — MarketBeat shows a consensus rating of Moderate Buy with an average target of $21.86 — while institutional investors own about 25.15% of the stock.
CervoMed Inc. (NASDAQ:CRVO - Get Free Report) CEO John Alam bought 4,447 shares of CervoMed stock in a transaction that occurred on Thursday, November 13th. The stock was bought at an average cost of $7.51 per share, with a total value of $33,396.97. Following the completion of the purchase, the chief executive officer owned 1,471,578 shares in the company, valued at approximately $11,051,550.78. This trade represents a 0.30% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.
CervoMed Trading Up 6.9%
CRVO stock opened at $8.21 on Tuesday. The stock has a 50-day moving average price of $7.84 and a two-hundred day moving average price of $8.13. CervoMed Inc. has a 1 year low of $1.80 and a 1 year high of $16.94. The stock has a market cap of $75.97 million, a PE ratio of -3.15 and a beta of -0.89.
CervoMed (NASDAQ:CRVO - Get Free Report) last issued its quarterly earnings results on Friday, November 7th. The company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). The firm had revenue of $0.32 million during the quarter, compared to the consensus estimate of $1.43 million. CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. On average, analysts forecast that CervoMed Inc. will post -1.88 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research firms have weighed in on CRVO. Roth Capital set a $20.00 price target on CervoMed and gave the stock a "buy" rating in a research report on Friday, October 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of CervoMed in a research report on Wednesday, October 8th. Canaccord Genuity Group increased their target price on shares of CervoMed from $21.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Zacks Research lowered shares of CervoMed from a "hold" rating to a "strong sell" rating in a research note on Monday, October 13th. Finally, Chardan Capital reissued a "buy" rating and set a $15.00 price target on shares of CervoMed in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $21.86.
View Our Latest Analysis on CRVO
Hedge Funds Weigh In On CervoMed
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers increased its holdings in CervoMed by 35.5% during the first quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock worth $53,000 after buying an additional 1,526 shares during the last quarter. Marshall Wace LLP bought a new position in shares of CervoMed in the 2nd quarter valued at about $76,000. Thompson Davis & CO. Inc. bought a new position in shares of CervoMed in the 2nd quarter valued at about $88,000. GSA Capital Partners LLP acquired a new position in shares of CervoMed during the 3rd quarter worth about $91,000. Finally, HighTower Advisors LLC bought a new stake in shares of CervoMed in the 1st quarter valued at about $104,000. 25.15% of the stock is owned by institutional investors.
About CervoMed
(
Get Free Report)
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
